17.31 USD
↗ 0.04 (0.23%)AT CLOSE (03:59 PM EDT)
Summit Therapeutics Inc. Common Stock
SMMTNASDAQ • USD
17.25
↘ 0.06 (0.33%)
POST MARKET (AS OF 04:35 PM EDT)
Post Market
AS OF 04:35 PM EDT
17.25
↘ 0.06 (0.33%)
Market: OPEN
Shares of Summit Therapeutics Inc. Common Stock (SMMT) are trading at $17.25. Technicals currently rate "Buy" while our fundamental analysis reads "Neutral". This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On the valuation front, SMMT trades at elevated multiples relative to its peers, earning a "Richly Valued" assessment.
Technical & fundamental data as of Oct 5, 2026.
Open?$17.49
High?$17.53
Low?$16.53
Prev. Close?$17.27
Volume?5.8M
Avg. Volume?7.1M
VWAP?$17.05
Rel. Volume?0.82x
Bid / Ask
Bid?$16.18 × 100
Ask?$18.19 × 100
Spread?$2.01
Midpoint?$17.19
Valuation & Ratios
Market Cap?13.8B
Shares Out?797.7M
Float?137.5M
Float %?17.3%
P/E Ratio?N/A
P/B Ratio?21.87
EPS?-$1.07
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Address
601 BRICKELL KEY DRIVE
MIAMI, FL 33131
Phone: 305-203-2034
MIAMI, FL 33131
Phone: 305-203-2034
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▲ Bullish(+3/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookNeutral
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?100
Momentum?77
Short Sent.?16
Piotroski F-Score?0/9Weak
Altman Z-Score?59.77Safe
Confidence?55%Low
Short InterestSqueeze Risk
Short % of Float?29.87%Squeeze Risk
Short Interest?41.1M
Days to Cover?6.6
Free Float137.5M
Avg Daily Volume6.3M
Settlement Date2026-09-15
Financial Health
Current Ratio?6.96Strong
Quick Ratio?6.96Strong
Cash Ratio?4.05Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score67/100
P/E?N/A▾
P/B?21.87HIGH▾
Peers50
S&P6
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-15.3CHEAP▾
Peers100
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-135.9%WEAK▾
Peers50
S&P3
ROA?-113.8%WEAK▾
Peers50
S&P3
Cash Flow & Enterprise
FCF?$-459822000
Enterprise Value?$13.4B
Fundamentals ratios updated end of day